AOD-9604 typical research dosing
Across the available literature, AOD-9604 is most commonly administered at 300–500 mcg per dose, 1 time(s) per day, via subcutaneous injection. Research protocols typically use 300–500 mcg subcutaneously once daily in a fasted state, often in the morning. Oral formulations were also studied in clinical trials at higher mg doses.
AOD-9604 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 5 mg AOD-9604 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 300 mcg | 400 mcg | 500 mcg |
|---|---|---|---|---|
| 1 mL | 5000 mcg/mL | 6.0 units | 8.0 units | 10.0 units |
| 2 mL | 2500 mcg/mL | 12.0 units | 16.0 units | 20.0 units |
| 3 mL | 1667 mcg/mL | 18.0 units | 24.0 units | 30.0 units |
| 5 mL | 1000 mcg/mL | 30.0 units | 40.0 units | 50.0 units |
AOD-9604 cycle length
Most reported AOD-9604 protocols run 12 weeks on, then 4 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
AOD-9604 half-life and timing
AOD-9604 has a half-life of approximately 0.75 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.